Vericel Corporation (VCEL)
Grows human cells to repair damaged knee cartilage and severe burn wounds
$46.71+0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+31.1%
The outlook
Vericel is trading near the upper end of its 52-week range, well above both its 50- and 200-day moving averages. Analyst consensus is strongly bullish, with an average price target about 22% above the current price. The stock carries a notably elevated trailing P/E ratio of 108.6, reflecting high market expectations.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 7 analysts
Price trendAbove its 50- & 200-day averages
52-week range90% of the way from its 52-week low to high
Price targetAvg target +22% vs current price
Analyst price target
~12-month · 7 analysts$57.14average target+22.3% vs now
Now $46.71
Low $46.00High $70.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.39B
52-wk high
$48.75
52-wk low
$28.95
50-day avg
$40.60
200-day avg
$37.12
Trailing P/E
108.6